A Phase 3 interventional study of Eltrombopag and Placebo in Non-alcoholic Steatohepatitis, Chronic Liver Disease and HCV, sponsored by GlaxoSmithKline. Terminated at 107 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-12.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 40th largest by enrollment of the 460 interventional ones that give a count, is one of 17 that started in 2008, is one of 29 in phase 3, and was the 35th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 17 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 292 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 9 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive procedures. The clinical benefit of eltrombopag will be measured by the proportion of subjects who avoid platelet transfusions, before, during and up to 7 days after undergoing an invasive procedure. In addition, bleeding events will be monitored during this time. The number of transfusions, safety events and medical resource utilisation will be monitored during this time and for up to 30 days after undergoing an invasive procedure to help further evaluate clinical benefit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non- (i.e., physiologically incapable of becoming pregnant) including any female who:
Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and within the 24 hour period prior to the first dose of product and uses one of the following acceptable methods of :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo, once daily, oral
Drug: Placebo
75 mg, once daily, oral
Drug: Eltrombopag
75 mg, once daily, oral
placebo, once daily, oral
Number of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures
A platelet transfusion was given if the platelet count was \<50 giga (10\^9) per liter (Gi/L) before the procedure. A platelet transfusion was not given if the platelet count was \>80 Gi/L (based on a primary endpoint of success). For participants with platelet counts between 50 Gi/L and 80 Gi/L, platelet transfusions were administered at the discretion of the investigator and the physician performing the elective invasive procedure.
Time frame: Prior to, during, and up to seven days following elective invasive procedures (Study Days 16-19); therefore, this covers a time period from Baseline to Day 26
Number of Participants With a World Health Organization (WHO) Bleeding Score >=2 During and up to 7 Days Following Elective Invasive Procedures
The WHO Bleeding Scale was used to assess bleeding during the study. The range of possible scores is 0 to 4. Grade 0 is no bleeding; Grade 1 is petechiae (small \[1-2 millimeter\] red or purple spot on the body, caused by a minor hemorrhage); Grade 2 is mild blood loss; Grade 3 is gross blood loss (requiring a transfusion; and Grade 4 is debilitating blood loss (retinal or cerebral associated with fatality).
Time frame: Prior to, during, and up to 7 days following elective invasive procedures (Study Days 16-19); therefore, this covers a time period from Baseline to Day 26
Number of Participants With the Indicated Number of Platelet Transfusions Administered
Platelet transfusion use was documented at every visit throughout the study from screening until the 4-week (30-day) post-procedure follow-up visit or at the time of participant withdrawal from the study.
Time frame: Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26
Median Platelet Count at Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 Day Follow-up; Early Withdrawal; and Maximum Post-baseline
Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).
Time frame: Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 day follow-up; early withdrawal; and maximum post-baseline
Number of Participants With the Indicated Platelet Count at Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 Day Follow-up (FU); and Maximum Post-baseline
Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).
Time frame: Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 day follow-up; and maximum post-baseline
Number of Participants Experiencing an Adverse Event (AEs) and Serious Adverse Event (SAEs) Within the Indicated Category
An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect or an ocular event of clinical concern. Medical or scientific judgement is exercised in deciding whether reporting is appropriate in other situations.
Time frame: Screening to Procedure +30 day follow-up or early withdrawal
Number of Participants With a Serious Adverse Event That Occurred in Greater Than One Participant
Time frame: Screening to Procedure +30 day follow-up or early withdrawal
Number of Participants With the Indicated Event Relating to Vision
The progression of pre-existing cataracts was measured by the use of slit lamp examination. Decrease in visual acuity is defined as the loss of 3 or more lines of visual acuity in either eye (0.3 log minimal angle of resolution \[logMAR\], 15 letters on the standard Early Treatment Diabetic Retinopathy Study chart).
Time frame: Screening or Baseline and at End of Study (Procedure +30 day follow-up or withdrawal visit)
Number of Participants With Renal Function Abnormality
Renal function abnormality was defined by threshold values for: serum creatinine: change from baseline of \>=0.3 and \<0.5 milligrams (mg)/deciliter (dL) (\>=26.6 and \<44.3 micromoles \[umol\]/L) or change from baseline of \>=0.5 mg/dL (\>=44.3 umol/L); microscopic urine analysis: cellular casts pathologic (as defined by local standards of microscopic urine analysis); urine protein/creatinine ratio (UP/CR): \>0.5 mg/mg; Glomerular Filtration Rate (GFR) as determined by the Cockcroft-Gault formula and urine dipstick test.
Time frame: Screening to Procedure +30 day follow-up or early withdrawal
Number of Participants With a Clinically Significant Change in Electrocardiogram (ECG) Results
A 12-lead ECG was obtained in duplicate at screening, baseline, Day 15, and withdrawal from the study. Participants rested supine for 5 minutes before the 12-lead ECG was recorded. A 30 second rhythm strip was obtained, and the ECG was calibrated, labelled, and initialled by the person performing the recording. A written, interpretive assessment detailing clinical significance was produced, dated, and signed off by the physician at the site.
Time frame: Screening, Baseline, Day 15, and Withdrawal
Pharmacokinetics (PK) of Eltrombopag, Steady State AUC(0-tau)
AUC(0-tau) is the area under a concentration versus time curve between dose interval following repeat dosing. It is a measure of systemic drug exposure.
Time frame: Day 14
Pharmacokinetics (PK) of Eltrombopag, Cmax
Cmax is the steady state peak plasma concentration of a drug observed after its administration.
Time frame: Day 14
Pharmacokinetics (PK) of Eltrombopag, t1/2
t1/2 is the half life of a drug based on its terminal phase. Half life is defined as the time necessary to halve the plasma concentration.
Time frame: Day 14
Pharmacokinetics (PK) of Eltrombopag, CL/F
CL/F is the apparent plasma clearance, where CL is an estimate of the total body clearance, and F is the fraction of dose absorbed. Total clearance is the volume of blood cleared of the drug by the various elimination processes (metabolism and excretion) per unit time.
Time frame: Day 14
Mean Number of Days Spent in the Hospital
The number of days spent in the hospital was analyzed as an indication of medical resource utilization throughout the study.
Time frame: Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26
Mean Number of Unscheduled Office Visits, Unscheduled Laboratory Tests, and Unscheduled Procedures
The number of unscheduled events was analyzed as an indication of medical resource utilization throughout the study.
Time frame: Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26
| Milestone | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Started | 147 | 145 |
| Completed | 127 | 127 |
| Not completed | 20 | 18 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Study closed/terminated | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 5 |
| Withdrew: Investigator discretion | 2 | 6 |
| Withdrew: Withdrew consent | 8 | 3 |
A platelet transfusion was given if the platelet count was \<50 giga (10\^9) per liter (Gi/L) before the procedure. A platelet transfusion was not given if the platelet count was \>80 Gi/L (based on a primary endpoint of success). For participants with platelet counts between 50 Gi/L and 80 Gi/L, platelet transfusions were administered at the discretion of the investigator and the physician performing the elective invasive procedure.
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Number of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures | 28 | 104 |
The WHO Bleeding Scale was used to assess bleeding during the study. The range of possible scores is 0 to 4. Grade 0 is no bleeding; Grade 1 is petechiae (small \[1-2 millimeter\] red or purple spot on the body, caused by a minor hemorrhage); Grade 2 is mild blood loss; Grade 3 is gross blood loss (requiring a transfusion; and Grade 4 is debilitating blood loss (retinal or cerebral associated with fatality).
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Number of Participants With a World Health Organization (WHO) Bleeding Score >=2 During and up to 7 Days Following Elective Invasive Procedures | 34 | 25 |
Platelet transfusion use was documented at every visit throughout the study from screening until the 4-week (30-day) post-procedure follow-up visit or at the time of participant withdrawal from the study.
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| 0 | 30 | 106 |
| 1 | 93 | 24 |
| 2 | 3 | 1 |
| 3 | 2 | 0 |
| 4 | 3 | 0 |
| 5 | 0 | 0 |
| 6 | 1 | 0 |
| Died/withdrew prior to any platelet transfusions | 15 | 14 |
Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).
| Gi/L | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Screening, n=147, 145 | 40.0 (8 to 70) | 40.0 (3 to 55) |
| Day 1, n=145, 141 | 40.0 (8 to 222) | 40.0 (12 to 62) |
| Day 8, n=139, 134 | 41.0 (6 to 190) | 58.5 (20 to 337) |
| Day 15, n=132, 131 | 39.0 (6 to 200) | 103.0 (25 to 397) |
| Days 16-19, n=50, 49 | 41.5 (18 to 250) | 107.0 (30 to 406) |
| Procedure + 7 day follow-up, n=128, 125 | 44.0 (17 to 150) | 148 (30 to 493) |
| Procedure + 14 day follow-up, n=116, 125 | 47.5 (13 to 370) | 110 (18 to 805) |
| Procedure + 21 day follow-up, n=120, 117 | 44.5 (11 to 200) | 62.0 (15 to 967) |
| Procedure + 30 day follow-up, n=125, 127 | 40.0 (10 to 200) | 50.0 (14 to 999) |
| Early withdrawal, n=9, 8 | 40.0 (11 to 195) | 41.0 (32 to 140) |
| Maximum post-baseline, n=144, 140 | 53.0 (16 to 370) | 152 (32 to 999) |
Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Screening, <50 Gi/L, n=147, 145 | 133 | 136 |
| Screening, >=50-<=80 Gi/L, n=147, 145 | 14 | 8 |
| Screening, >80-<=200 Gi/L, n=147, 145 | 0 | 0 |
| Screening, >200-<=400 Gi/L, n=147, 145 | 0 | 0 |
| Screening, >400 Gi/L, n=147, 145 | 0 | 0 |
| Day 8, <50 Gi/L, n=139, 135 | 98 | 48 |
| Day 8, >=50-<=80 Gi/L, n=139, 135 | 34 | 50 |
| Day 8, >80-<=200 Gi/L, n=139, 135 | 7 | 33 |
| Day 8, >200-<=400 Gi/L, n=139, 135 | 0 | 3 |
| Day 8, >400 Gi/L, n=139, 135 | 0 | 0 |
| Day 15, <50 Gi/L, n=132, 131 | 98 | 14 |
| Day 15, >=50-<=80 Gi/L, n=132, 131 | 26 | 31 |
| Day 15, >80-<=200 Gi/L, n=132, 131 | 8 | 67 |
| Day 15, >200-<=400 Gi/L, n=132, 131 | 0 | 19 |
| Day 15, >400 Gi/L, n=132, 131 | 0 | 0 |
| Procedure + 7 Day FU, <50 Gi/L, n=128, 126 | 78 | 11 |
| Procedure + 7 Day FU, >=50-<=80 Gi/L, n=128, 126 | 38 | 20 |
| Procedure + 7 Day FU, >80-<=200 Gi/L, n=128, 126 | 12 | 60 |
| Procedure + 7 Day FU, >200-<=400 Gi/L, n=128, 126 | 0 | 30 |
| Procedure + 7 Day FU, >400 Gi/L, n=128, 126 | 0 | 4 |
| Procedure + 14 Day FU, <50 Gi/L, n=117, 125 | 63 | 22 |
| Procedure + 14 Day FU, >=50-<=80 Gi/L, n=117, 125 | 40 | 21 |
| Procedure + 14 Day FU, >80-<=200 Gi/L, n=117, 125 | 11 | 62 |
| Procedure + 14 Day FU, >200-<=400 Gi/L, n=117, 125 | 2 | 17 |
| Procedure + 14 Day FU, >400 Gi/L, n=117, 125 | 0 | 3 |
| Procedure + 21 Day FU, <50 Gi/L, n=121, 117 | 80 | 38 |
| Procedure + 21 Day FU, >=50-<=80 Gi/L, n=121, 117 | 30 | 33 |
| Procedure + 21 Day FU, >80-<=200 Gi/L, n=121, 117 | 10 | 38 |
| Procedure + 21 Day FU, >200-<=400 Gi/L, n=121, 117 | 0 | 7 |
| Procedure + 21 Day FU, >400 Gi/L, n=121, 117 | 0 | 1 |
| Maximum Post-Baseline, <50 Gi/L, n=144, 140 | 60 | 11 |
| Maximum Post-Baseline, >=50-<=80 Gi/L, n=144, 140 | 53 | 23 |
| Maximum Post-Baseline, >80-<=200 Gi/L, n=144, 140 | 28 | 62 |
| Maximum Post-Baseline, >200-<=400 Gi/L, n=144, 140 | 3 | 37 |
| Maximum Post-Baseline, >400 Gi/L, n=144, 140 | 0 | 7 |
An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect or an ocular event of clinical concern. Medical or scientific judgement is exercised in deciding whether reporting is appropriate in other situations.
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| AEs during study | 85 | 79 |
| Drug-related AEs in >1 participant | 15 | 31 |
| Throboembolic AEs | 2 | 6 |
| Bleeding AEs | 25 | 19 |
| Hepatobiliary AEs | 16 | 24 |
| Malignancy AEs | 1 | 1 |
| Renal AEs | 4 | 2 |
| Death on study | 2 | 3 |
| SAEs in >1 participant during study | 17 | 19 |
| Drug-related SAEs in >1 participant | 4 | 9 |
| Thrombocytopenia | 1 | 1 |
| Progression of pre-existing cataract n=145,143 | 2 | 0 |
| Incident cataract develpment n=145,143 | 2 | 4 |
| Decrease in visual acuity n=121,124 | 19 | 21 |
| Renal function abnormality n=145,143 | 27 | 28 |
| Clinically significant change in ECG n=128,130 | 0 | 1 |
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Number of Participants With a Serious Adverse Event That Occurred in Greater Than One Participant | 4 | 9 |
The progression of pre-existing cataracts was measured by the use of slit lamp examination. Decrease in visual acuity is defined as the loss of 3 or more lines of visual acuity in either eye (0.3 log minimal angle of resolution \[logMAR\], 15 letters on the standard Early Treatment Diabetic Retinopathy Study chart).
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Progression of pre-existing cataract, n=145, 143 | 2 | 0 |
| Cataract development, n=145, 143 | 2 | 4 |
| Decrease in visual acuity, n=121, 124 | 19 | 21 |
Renal function abnormality was defined by threshold values for: serum creatinine: change from baseline of \>=0.3 and \<0.5 milligrams (mg)/deciliter (dL) (\>=26.6 and \<44.3 micromoles \[umol\]/L) or change from baseline of \>=0.5 mg/dL (\>=44.3 umol/L); microscopic urine analysis: cellular casts pathologic (as defined by local standards of microscopic urine analysis); urine protein/creatinine ratio (UP/CR): \>0.5 mg/mg; Glomerular Filtration Rate (GFR) as determined by the Cockcroft-Gault formula and urine dipstick test.
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Number of Participants With Renal Function Abnormality | 27 | 28 |
A 12-lead ECG was obtained in duplicate at screening, baseline, Day 15, and withdrawal from the study. Participants rested supine for 5 minutes before the 12-lead ECG was recorded. A 30 second rhythm strip was obtained, and the ECG was calibrated, labelled, and initialled by the person performing the recording. A written, interpretive assessment detailing clinical significance was produced, dated, and signed off by the physician at the site.
| participants | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Number of Participants With a Clinically Significant Change in Electrocardiogram (ECG) Results | 0 | 1 |
AUC(0-tau) is the area under a concentration versus time curve between dose interval following repeat dosing. It is a measure of systemic drug exposure.
| hour*micrograms (ug)/milliliter (mL) | Eltrombopag 75 mg |
|---|---|
| Pharmacokinetics (PK) of Eltrombopag, Steady State AUC(0-tau) | 250 (211 to 296) |
Cmax is the steady state peak plasma concentration of a drug observed after its administration.
| ug/mL | Eltrombopag 75 mg |
|---|---|
| Pharmacokinetics (PK) of Eltrombopag, Cmax | 11.6 (9.8 to 13.6) |
t1/2 is the half life of a drug based on its terminal phase. Half life is defined as the time necessary to halve the plasma concentration.
| hours | Eltrombopag 75 mg |
|---|---|
| Pharmacokinetics (PK) of Eltrombopag, t1/2 | 70.3 (60.7 to 81.5) |
CL/F is the apparent plasma clearance, where CL is an estimate of the total body clearance, and F is the fraction of dose absorbed. Total clearance is the volume of blood cleared of the drug by the various elimination processes (metabolism and excretion) per unit time.
| Liters/hour | Eltrombopag 75 mg |
|---|---|
| Pharmacokinetics (PK) of Eltrombopag, CL/F | 0.30 (0.25 to 0.36) |
The number of days spent in the hospital was analyzed as an indication of medical resource utilization throughout the study.
| days | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Mean Number of Days Spent in the Hospital | 1.3 ± 3.77 | 1.7 ± 6.43 |
The number of unscheduled events was analyzed as an indication of medical resource utilization throughout the study.
| unscheduled events | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Unscheduled office visits | 0.8 ± 1.64 | 1.0 ± 2.91 |
| Unscheduled laboratory tests | 1.1 ± 3.78 | 1.8 ± 5.67 |
| Unscheduled procedures | 0.3 ± 0.81 | 0.4 ± 1.65 |
Collected over Adverse events (AEs) and serious adverse events (SAEs) with an onset on or after the start date of study medication were collected until the end of the study (up to the end of Week 7).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 17/145 (11.7%) | 35/145 (24.1%) |
| Eltrombopag 75 mg | — | 19/143 (13.3%) | 40/143 (28%) |
| Event | Placebo | Eltrombopag 75 mg |
|---|---|---|
| Portal vein thrombosisHepatobiliary disorders | 2/145 | 4/143 |
| Mesenteric vein thrombosisGastrointestinal disorders | 1/145 | 3/143 |
| CataractEye disorders | 3/145 | 1/143 |
| Hepatic encephalopathyNervous system disorders | 3/145 | 2/143 |
| SepsisInfections and infestations | 0/145 | 2/143 |
| Rectal haemorrhageGastrointestinal disorders | 2/145 | 0/143 |
| Abdominal painGastrointestinal disorders | 0/145 | 1/143 |
| Appendix disorderGastrointestinal disorders | 0/145 | 1/143 |
| AscitesGastrointestinal disorders | 0/145 | 1/143 |
| Ileus paralyticGastrointestinal disorders | 0/145 | 1/143 |
| Event | Placebo | Eltrombopag 75 mg |
|---|---|---|
| HeadacheNervous system disorders | 6/145 | 11/143 |
| PyrexiaGeneral disorders | 10/145 | 8/143 |
| Abdominal painGastrointestinal disorders | 7/145 | 7/143 |
| NauseaGastrointestinal disorders | 7/145 | 7/143 |
| DiarrhoeaGastrointestinal disorders | 5/145 | 7/143 |
| Age, Continuous(Years) | Placebo | Eltrombopag 75 mg | Total |
|---|---|---|---|
| Mean | 53.5 ± 11.78 | 51.6 ± 11.04 | 52.5 ± 11.44 |
| Sex: Female, Male(Participants) | Placebo | Eltrombopag 75 mg | Total |
|---|---|---|---|
| Female | 55 | 49 | 104 |
| Male | 92 | 96 | 188 |
| Race/Ethnicity, Customized(participants) | Placebo | Eltrombopag 75 mg | Total |
|---|---|---|---|
| White | 93 | 85 | 178 |
| Central/South Asian Heritage | 33 | 41 | 74 |
| Japanese/East Asian/South East Asian Heritage | 19 | 14 | 33 |
| African American/African Heritage | 2 | 4 | 6 |
| Native Hawaiian/Other Pacific Islander and White | 0 | 1 | 1 |
| Number of participants categorized into the indicated Child-Pugh (CP) Class(participants) | Placebo | Eltrombopag 75 mg | Total |
|---|---|---|---|
| Child-Pugh Class A | 59 | 68 | 127 |
| Child-Pugh Class B | 64 | 57 | 121 |
| Child-Pugh Class C | 17 | 10 | 27 |
| Model for End-Stage Liver Disease (MELD) Score at Baseline(scores on a scale) | Placebo | Eltrombopag 75 mg | Total |
|---|---|---|---|
| Median | 12 (6 to 25) | 12 (6 to 24) | 12 (6 to 25) |
Showing the first 100 of 107 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 1 month after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Non-alcoholic Fatty Liver Disease →